SUNNYVALE, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Cepheid , announced today that it has taken an additional license to the Scorpions(TM) technology for use in the human in-vitro diagnostics market from DxS Ltd., a private U.K. based company focused on personalized medicine.
"Cepheid is a broad based molecular company, as such; we want to have access to a variety of technological approaches to provide the best solution to an individual problem. Based on our industrial experience we have found the Scorpions(TM) technology to provide benefits in speed and in developing highly multiplexed tests. As we continue to develop our clinical molecular diagnostic program, we want to enable our scientists to have access to this technology for clinical application as appropriate. As noted with our previous announcement of the license for the industrial rights, we expect the technology to be applicable to both our SmartCycler(R) and GeneXpert(R) Systems," stated John Bishop, Cepheid's Chief Executive Officer.
About Cepheid
Cepheid , based in Sunnyvale, California, is a leading developer, manufacturer and marketer of fully integrated systems that enable genetic assessment when and where it is needed. Founded in 1996, the company is commercializing its technology and products worldwide for research, medical, and industrial applications requiring assessment of the human genome, infectious disease and biothreat agents. For more information on Cepheid please see www.cepheid.com.
Cepheid, SmartCycler(R) and GeneXpert(R) are registered trademarks of Cepheid in the United States and other countries. Other trademarks are the properties of their respective owners.
About DxS Ltd
DxS is an established genotyping products and services company providing pharmaceutical, biotechnology and clinical research companies with rapid and reliable pharmacogenetic analysis to support drug discovery, clinical development and personalised medicine. DxS operates from purpose built laboratories equipped with fully automated sample handling and genotyping systems in Manchester, UK. .
For more information on DxS please see www.dxsgenotyping.com For further information, please contact: DxS Ltd Dr Stephen Little, Chief Executive Officer Tel: +44 (0) 161 606 7201 (switch) stephen.little@dxsgenotyping.com De Facto Communications Maria Payne Tel: +44 (0) 207 940 1000 m.payne@defacto.com
This press release contains forward-looking statements that are not purely historical regarding Cepheid's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to future product development activities and product performance. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: uncertainty of market acceptance of any new products that may be developed; unforeseen research, development and manufacturing problems, which could delay the introduction of new products; unforeseen manufacturing costs; the need for additional licenses for new tests and other products and the terms of such licenses; the performance of new products; and underlying market conditions worldwide. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2004 and in its most recent quarterly report on Form 10-Q, each filed with the Securities and Exchange Commission.
All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to Cepheid, and Cepheid assumes no obligation to update any such forward-looking statement or reasons why results might differ.
At the Company: John L. Bishop CEO, Cepheid 408-541-4191 john.bishop@cepheid.com John R. Sluis CFO, Cepheid 408-541-4191 john.sluis@cepheid.com Financial Relations Board: Tricia Ross Investor/Analyst Information 617-520-7064 tross@financialrelationsboard.com
CepheidCONTACT: John L. Bishop, CEO, +1-408-541-4191, john.bishop@cepheid.com, orJohn R. Sluis, CFO, +1-408-541-4191, john.sluis@cepheid.com, both ofCepheid; or Investor/Analyst, Tricia Ross, of Financial Relations Board,+1-617-520-7064, tross@financialrelationsboard.com, for Cepheid; or DrStephen Little, Chief Executive Officer, DxS Ltd., +44-0-161 606-7201,stephen.little@dxsgenotyping.com; or Maria Payne of De FactoCommunications, +44-0-207-940 1000, m.payne@defacto.com, for DxS Ltd.
